rofecoxib
information and resources from the National Cancer Institute
rofecoxib
A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties. Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2.
|
|
|
|
news articles
Benedictine College Discovery Day Speaker Focuses on Ethics, Drugs ... Mar 27, 2006
PR Web (press release), In August 2004, Graham completed a study of myocardial infarction risk with rofecoxib (Vioxx), showing that it substantially increased patient risk. ...
Adequate Pain Control May Facilitate Better Results in Total Knee ... Mar 28, 2006
DG News ...between 2003 and 2004. Before the operation, the patients received Vioxx (rofecoxib), oxycodone and coumadin. After the replacement ...
Response to Expression of Concern Mar 15, 2006
New England Journal of Medicine (subscription), Three additional myocardial infarctions in the rofecoxib group and one additional stroke in the naproxen group were reported between February 16 and February 22 ...
Thomson Scientific Names 'Red-Hot' Research Papers of 2005 Mar 20, 2006
International News Service, ...in a clinical trial for colorectal adenoma prevention" 4 RS "Cardiovascular events New England 93 Bresalier, associated with rofecoxib Journal of Med. et al. ...
Los 10 artículos más citados en la literatura médica Mar 22, 2006
AZprensa, 4 (93 citas).- RS Bresalier, et al., "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial," New Engl. ...
Celecoxib Increases Risk Of Heart Attack, New Study Finds Mar 2, 2006
Medical News Today (press release), Rofecoxib, also a COX-2 inhibitor drug, was manufactured by drug company Merck under the name Vioxx but voluntarily withdrawn worldwide following evidence ...
Man claims heart attack from taking Vioxx Mar 6, 2006
St. Clair Record, 30, 2004, because a study indicated it could cause cardiac problems, is the brand name of rofecoxib, a cox-2 inhibitor and a non-steroidal anti-inflammatory ...
New advertising code of conduct established in Vioxx withdrawal ... Mar 9, 2006
Pharmaceutical Business Review However, the withdrawal of Merck & Co's painkiller Vioxx (rofecoxib) in September 2004 brought the issue of drug safety to the forefront and has had a ...
Research Misconduct, Retraction, and Cleansing the Medical ... Mar 7, 2006
Annals of Internal Medicine Expression of concern: Bombardier, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. ...
Meta-Analysis Links Celebrex to Doubling of MI Risk Mar 2, 2006
MedPage Today, ...this increased risk for MI, which was 2.26-fold compared with placebo, is similar to the 2.24-fold increased risk reported for Vioxx (rofecoxib), which Merck ...
The USA is the World's Largest and Wealthiest Pharmaceutical ... Mar 6, 2006
Business Wire (press release), The question of drug safety has come under intense scrutiny following the September 2004 withdrawal of Vioxx (rofecoxib) from the market. ...
NicOx announces initiation of phase 3 trial for HCT 3012 in Dec 19, 2005
Companynewsgroup (Comunicati stampa), The OASIS trial demonstrated that HCT 3012 375 mg and 750 mg bid were superior to placebo (p<0.001) and non-inferior to rofecoxib 25 mg per day (p<0.001) in ...
Three myocardial infarctions with Vioxx were not included in VIGOR ... Dec 9, 2005
Xagena.it, ...was designed primarily to compare gastrointestinal events in patients with rheumatoid arthritis randomly assigned to the treatment with Rofecoxib ( Vioxx ) or ...
Hundreds seek compo over Vioxx drug Dec 14, 2005
The Age, The writ alleges that Merck failed to warn health professionals and users that Vioxx contained rofecoxib - an ingredient that more than doubles the risk of ...
Painkiller Study Aims to Answer Safety Questions Dec 14, 2005
MedPage Today, Steven Nissen, MD, the Cleveland Clinic cardiologist who was an early and outspoken critic of Vioxx (rofecoxib), Merck's once popular Cox 2 inhibitor, is the ...
Pfizer sponsors major Celebrex safety study Dec 15, 2005
Pharma Times (subscription), Celebrex is the last remaining COX-2 inhibitor on the market, after Merck & Co's Vioxx (rofecoxib) and Pfizer's Bextra (valdecoxib) were withdrawn from sale ...
Merck boosts cost cuts by $1 billion Dec 16, 2005
Pharma Times (subscription), ...for 2006 as a whole, as well as the potentially huge liabilities the company faces in lawsuits alleging injury by its now-withdrawn painkiller Vioxx (rofecoxib ...
NSAIDs Ups Risk of Dying After a Myocardial Infarction: Presented ... Nov 22, 2005
DG News Their results show that 5.2% of patients had prescriptions for rofecoxib, 4.3% celecoxib, 17.5% ibuprofen, 10.6% diclofenac, and 12.7% had taken other NSAIDs. ...
Publication claims Merck withheld information Dec 8, 2005
Brazosport Facts (subscription), ...“Lack of inclusion of the three events resulted in an understatement of the difference in risk of (heart attacks) between the rofecoxib and naproxen groups ...
Plaintiffs seek mistrial in federal Vioxx case Dec 12, 2005
Pharma Times (subscription), The lawsuit has been brought by the widow of Richard Irvin, a 53-year-old man who died of a heart attack after taking Vioxx (rofecoxib) for about a month to ...
Journal accuses Vioxx study authors of omitting data Dec 9, 2005
Pharma Times (subscription), A medical journal has asked the authors of a pivotal study of Merck & Co's withdrawn painkiller Vioxx (rofecoxib) to correct a published article on the trial ...
Third Vioxx Suit Is a Mistrial Dec 12, 2005
MedPage Today, 12 - A federal jury in the third liability suit over purported cardiac damages from the use of Vioxx (rofecoxib) declared itself deadlocked today, and the ...
The Vioxx Mistrial Dec 13, 2005
New York Sun, ...published in the Journal's November 23, 2000, issue under the eye-catching headline "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in ...
Mistrial ruling bad news for Merck Dec 13, 2005
Pharma Times (subscription), The judge in the federal drug liability trial involving Merck & Co's withdrawn painkiller Vioxx (rofecoxib) has declared a mistrial after the jury failed to ...
Study Questions Greater GI Safety of COX-2 Inhibitors Dec 2, 2005
Medscape (subscription) NEW YORK (Reuters Health) Dec 01 - COX-2 selective inhibitors, such as rofecoxib (Vioxx) or celecoxib (Celebrex), have been billed as pain relievers with a ...
Licensing provides hope for big pharma’s woes Dec 13, 2005
PharmaLive.com (press release), It appears that the withdrawal of Vioxx (rofecoxib) may have had repercussions throughout the company, resulting in a slowdown in licensing activity- maybe to ...
No Evidence That COX-2 Inhibitors Provide Greater Stomach ... Dec 5, 2005
Medical News Today (press release), Risks were reduced after adjusting for other factors, but remained significantly increased for naproxen, diclofenac, and rofecoxib, but not for current use of ...
No evidence that COX-2 inhibitors provide greater gastroprotection Dec 9, 2005
Xagena.it, ...for other factors, but remained significantly increased for Naproxen ( Aleve/Naprosyn ), Diclofenac ( Cataflam/Voltaren ), and Rofecoxib ( Vioxx ), but not for ...
Visiting Veterinarian: Arthritis pain relief for Rover Dec 7, 2005
Martha's Vineyard Times, The equivalent human products are drugs like celecoxib (Celebrex), rofecoxib (Vioxx), and valdecoxib (Bextra.) But wait, you say. ...
New England Journal Editors Find They Were Hoodwinked on Vioxx ... Dec 8, 2005
MedPage Today, 8 - Chagrined editors of the New England Journal of Medicine said today they just discovered that the authors of a Vioxx (rofecoxib) study published five years ...
Cox-2 Inhibitors Not Safer for Stomach Dec 1, 2005
Forbes ...the data to account for other factors, the risk remained significantly high for the cox-2 inhibitors naproxen, diclofenac (Voltaren) and rofecoxib (Vioxx). ...
Cox-2 Inhibitors Not Safer for Stomach Dec 2, 2005
ABC News Even after adjusting the data to account for other factors, the risk remained significantly high for the cox-2 inhibitor rofecoxib (Vioxx) and the NSAIDs ...
Blocking hormone may reduce stroke damage Nov 30, 2005
Science Daily (press release) 13, 2005) -- Scientists say they may have found the cause of increased rates of heart problems in patients taking the cox-2 inhibitor painkiller rofecoxib ...
Top Cardiologist Highly Critical of Merck Placing Vioxx Profits ... Dec 5, 2005
Newsinferno.com, On Nov. 21, 1996, a Memo by a Merck official shows the company wrestling with the issue of Vioxx' (Rofecoxib) involvement in increased cardiovascular events. ...
Painkillers and Upset Stomachs Dec 2, 2005
Ivanhoe, In 2004, one of the most popular of the class, rofecoxib known as Vioxx, was voluntarily withdrawn from the market because of evidence linking it to ...
High Number Of Dropouts Spoil Oxytrex Phase III Trial Nov 22, 2005
BioWorld Online (subscription), ...osteoarthritis patients but nonetheless appeared to have enrolled soon after last year's market withdrawal of the COX-2 inhibitor Vioxx (rofecoxib, Merck & Co. ...
New Study Finds COX-2 Inhibitors Are Not Safer for the Stomach Dec 5, 2005
Newsinferno.com, ...killers. The risk was significantly higher for the COX-2 inhibitors naproxen, and rofecoxib (Vioxx), and diclofenac (Voltaren). ...
New Drugs from GlaxoSmithKline, Novartis, NicOx, and Pain ... Nov 30, 2005
PR Newswire (press release), ...will restore the drug market for the treatment of arthritic pain following the highly-publicized withdrawals of Merck's Vioxx (rofecoxib) and Pfizer's Bextra ...
Are safety labeling and safety warnings enough? Nov 23, 2005
Naples Sun Times, ...or deaths. After losing several cases in the past few months, Merck won a VIOXX (rofecoxib) trial a few weeks ago. Defense argued ...
FDA considers Tamiflu safety in children Nov 18, 2005
New Scientist (subscription), ...drugs prescribed to children. Seven others, including the controversial Vioxx (rofecoxib), are being considered. The FDA notes: “Based ...
Pharm Land Nov 18, 2005
New York Times, Whatever the case, it certainly makes a nice break from all the dreary paragraphs about prostaglandins, rofecoxib and Heliobacter pylori. ...
Strange facts, odd figures Nov 18, 2005
Farang Untamed Travel, Dr. Petpiboon Prasit, a Thai chemist working in a big San Diego laboratory, has pioneered a drug called Vioxx, or Rofecoxib, which has fomented a revolution in ...
|
|
